Bicara Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell BCAX and other ETFs, options, and stocks.About BCAX
Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and develops biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company’s bi-functional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor.
CEOClaire Mazumdar
CEOClaire Mazumdar
Employees55
Employees55
HeadquartersBoston, Massachusetts
HeadquartersBoston, Massachusetts
Founded2018
Founded2018
Employees55
Employees55
BCAX Key Statistics
Market cap997.03M
Market cap997.03M
Price-Earnings ratio-8.16
Price-Earnings ratio-8.16
Dividend yield—
Dividend yield—
Average volume694.62K
Average volume694.62K
High today$19.18
High today$19.18
Low today$18.18
Low today$18.18
Open price$18.90
Open price$18.90
Volume701.63K
Volume701.63K
52 Week high$22.68
52 Week high$22.68
52 Week low$7.80
52 Week low$7.80
Stock Snapshot
As of today, Bicara Therapeutics(BCAX) shares are valued at $18.20. The company's market cap stands at 997.03M, with a P/E ratio of -8.16.
As of 2025-12-07, Bicara Therapeutics(BCAX) stock has fluctuated between $18.18 and $19.18. The current price stands at $18.20, placing the stock +0.1% above today's low and -5.1% off the high.
Bicara Therapeutics(BCAX) shares are trading with a volume of 701.63K, against a daily average of 694.62K.
In the last year, Bicara Therapeutics(BCAX) shares hit a 52-week high of $22.68 and a 52-week low of $7.80.
In the last year, Bicara Therapeutics(BCAX) shares hit a 52-week high of $22.68 and a 52-week low of $7.80.
Analyst ratings
89%
of 9 ratingsBuy
88.9%
Hold
11.1%
Sell
0%
People also own
Based on the portfolios of people who own BCAX. This list is generated using Robinhood data, and it’s not a recommendation.